Who are cefuroxime plus erythromycin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Vonoprazan, Amoxicillin and Clarithromycin, Rabeprazloe+bismuth+amoxicillin+clarithromycin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cefuroxime-plus-erythromycin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

cefuroxime plus erythromycin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

cefuroxime plus erythromycin (cefuroxime plus erythromycin) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam antibiotic + macrolide antibiotic combination. Area: Infectious Disease.

phase 3 Beta-lactam antibiotic + macrolide antibiotic combination Bacterial cell wall (penicillin-binding proteins) and bacterial 50S ribosome Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

cefuroxime plus erythromycin (cefuroxime plus erythromycin) — Pfizer. This combination uses cefuroxime (a beta-lactam antibiotic) to inhibit bacterial cell wall synthesis and erythromycin (a macrolide) to inhibit bacterial protein synthesis, providing broad-spectrum coverage against respiratory pathogens.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
cefuroxime plus erythromycin TARGET	cefuroxime plus erythromycin	Pfizer	phase 3	Beta-lactam antibiotic + macrolide antibiotic combination	Bacterial cell wall (penicillin-binding proteins) and bacterial 50S ribosome
Vonoprazan, Amoxicillin and Clarithromycin	Vonoprazan, Amoxicillin and Clarithromycin	Kaohsiung Medical University	marketed	Potassium-competitive acid blocker (PCAB) + beta-lactam antibiotic + macrolide antibiotic combination	H+/K+-ATPase (vonoprazan); bacterial cell wall and protein synthesis (amoxicillin and clarithromycin)
Rabeprazloe+bismuth+amoxicillin+clarithromycin	Rabeprazloe+bismuth+amoxicillin+clarithromycin	Xijing Hospital of Digestive Diseases	marketed	Proton pump inhibitor + bismuth salt + beta-lactam antibiotic + macrolide antibiotic combination	H+ ATPase (rabeprazole); H. pylori urease and cell wall (bismuth); bacterial peptidoglycan (amoxicillin); bacterial ribosome (clarithromycin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-lactam antibiotic + macrolide antibiotic combination class)

Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). cefuroxime plus erythromycin — Competitive Intelligence Brief. https://druglandscape.com/ci/cefuroxime-plus-erythromycin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing